Vanda Pharmaceuticals Q4 Revenue Rises 15% to $75M, Net Loss Widens to $30M
Vanda Pharmaceuticals reported Q4 2025 revenue of $75 million, a 15% year-over-year increase, while net loss widened to $30 million from $18 million in Q4 2024. R&D expenses climbed 22% to $28 million, and year-end cash and investments totaled $120 million, funding operations into mid-2026.
1. Q4 2025 Financial Results
Vanda achieved product and service revenue of $75 million in Q4 2025, up 15% from $65 million a year earlier, driven by increased market uptake of its sleep disorder treatment. However, higher operating costs led to a net loss of $30 million, compared with an $18 million loss in Q4 2024.
2. Operating and R&D Expenses
Total R&D spending rose 22% to $28 million as the company advanced late-stage clinical trials for its neuropsychiatric pipeline. SG&A expenses increased modestly to $20 million, reflecting expanded commercial efforts.
3. Cash Position and Outlook
Vanda ended the quarter with $120 million in cash and investments, providing a cash runway through mid-2026. Management reiterated plans to continue investing in pipeline assets while targeting profitability through revenue growth and cost management.